CMC benefits from infrastructure tailwinds and efficiency gains, but macroeconomic and tariff uncertainties warrant caution ...

U.S. stocks end the week on a high, as S&P 500 reclaims the 6,000-point mark for the first time since February. Read more ...

Fresenius offers international diversification, stable healthcare exposure, and upside from a strategic pivot. Find out why ...

USCL ETF has climate-conscious exposure to top companies like Nvidia and Microsoft with a low expense ratio. Read an in-depth ...

TFI International remains a strong buy with solid cash flow, strategic growth, and new buying opportunities amid a recovering ...

CAVA's expansion boosts revenue, but slowing sales and high valuation raise concerns. Read here for an analysis of CAVA stock ...

Northwest Pipe's growth is set to surge in FY25, with improving margins, strong order momentum, and favorable stock valuation ...

Omada Health shows strong growth and innovation in chronic care but remains unprofitable with valuation, churn. See why OMDA ...

Torrid Holdings faces revenue challenges, e-commerce risks, and industry pressures. See here to know why we recommend a sell ...

Demand for private credit continues to surge, with projections suggesting it could hit $2.8 trillion by 2028. Read more here.

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

Aker ASA remains discounted to NAV, with steps like the Solstad IPO and Cognite's U.S. shift supporting value. See why AKAAF ...